VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $20,260.03 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 1,211 shares of the business’s stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $16.73, for a total value of $20,260.03. Following the sale, the insider owned 3,559,243 shares of the company’s stock, valued at approximately $59,546,135.39. This represents a 0.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43.

VanEck Biotech ETF Stock Performance

Shares of BBH traded up $2.26 on Thursday, reaching $206.25. The company’s stock had a trading volume of 3,431 shares, compared to its average volume of 6,008. The stock’s 50 day simple moving average is $192.26 and its two-hundred day simple moving average is $191.76. VanEck Biotech ETF has a 12-month low of $154.75 and a 12-month high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

Hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. increased its stake in shares of VanEck Biotech ETF by 40,463.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after purchasing an additional 492,843 shares in the last quarter. Ascent Advisors LLC purchased a new position in VanEck Biotech ETF during the first quarter valued at $11,178,000. Raymond James Financial Inc. lifted its position in VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock valued at $10,414,000 after purchasing an additional 48,297 shares in the last quarter. Bank of America Corp DE grew its holdings in VanEck Biotech ETF by 44.3% during the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after purchasing an additional 20,375 shares during the period. Finally, LPL Financial LLC increased its position in VanEck Biotech ETF by 63.5% in the fourth quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock worth $6,021,000 after buying an additional 12,351 shares in the last quarter. Institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.